TriangleSasanlimab (NCT07123090)
Sasanlimab trial for Metastatic Renal Cell Carcinoma (NCT07123090). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable advanced or metastatic kidney cancer with a clear-cell component or a TFE3/TFEB translocation. Prior systemic treatment for advanced disease is excluded.
The idea: sasanlimab blocks PD-1, palbociclib blocks cell-cycle proteins CDK4/6, and axitinib targets blood-vessel growth signaling. Sasanlimab is injected under the skin on day each 28-day cycle. Oral axitinib is taken twice daily; oral palbociclib is added on days 8–28. Researchers measure tumor responses.
This phase 2 study plans 25 patients. Stephanie Berg leads at Dana-Farber; two Boston sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.